NCT Number: NCT01843192
Powered Echelon Device in VATS Surgery
This study aims to collect real world outcomes of Video-Assisted Thoracoscopic Surgery (VATS) for lung cancer (lobectomy, wedge resection) using ECHELON FLEX™ Powered ENDOPATH® Staplers 45 mm and/or 60 mm (study devices).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Dignity Health, St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Suspected or confirmed NSCLC (up to and including Stage II)
- Scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung
- Performance status 0-1 (Eastern Cooperative Oncology Group classification)
- ASA score < 3
- No prior history of VATS or open lung surgery
- Willing to give consent and comply with study-related evaluation and treatment schedule
Exclusion criteria
- Active bacterial infection or fungal infection;
- Systemic administration (intravenous or oral) of steroids (within 30 days prior to study procedure)
- Chemotherapy or radiation therapy for lung cancer may not be performed for 30 days prior to the procedure
- Scheduled concurrent surgical procedure other than wedge resection or lobectomy (central venous access - e.g. port placement, mediastinoscopy with lymph node sampling, and VATS lymphadenectomy are allowed)
- Pregnancy
- Physical or psychological condition which would impair study participation;
- The patient is judged unsuitable for study participation by the Investigator for any other reason; or
- Unable or unwilling to attend follow-up visits and examinations
Treatment and study plan
Primary outcomes
-
Occurrence of Postoperative Air Leaks
Time frame: Post-operative period through hospital discharge and follow-up at Day 30
Air leak was to be quantitatively assessed starting on the evening after surgery and then twice daily (during morning and evening rounds) as described by Certfolio et al. 2001. Patients were instructed to perform standardized repeated forced expiratory maneuvers (coughing and blowing). Leaks were scored using the air-leak meter that comes as part of a pleura vac system from 1 to 7, with 7 being the highest (most chambers).
-
Occurrence of Prolonged Air Leaks
Time frame: Post-operative period through hospital discharge and follow-up at Day 30
Prolonged air leaks defined as longer than 5 days in continuous duration. Air leak was to be quantitatively assessed starting on the evening after surgery and then twice daily (during morning and evening rounds) as described by Certfolio et al. 2001. Patients were instructed to perform standardized repeated forced expiratory maneuvers (coughing and blowing). Leaks were scored using the air-leak meter that comes as part of a pleura vac system from 1 to 7, with 7 being the highest (most chambers).
Secondary outcomes
-
Length of Stay (LOS)
Time frame: Post-operative period through hospital discharge and follow-up at Day 30
Determined as the length of time in days from hospital admission to initial hospital discharge
-
Volume of Estimated Intra-operative Blood Loss
Time frame: Blood loss intra-op and up to 5 days post-op
-
Time to Chest Tube Removal
Time frame: Post-operative period through hospital discharge and follow-up at Day 30
Defined as the number of days from date of surgery to removal of the last chest tube inserted during the surgical procedure.
-
Operative Time
Time frame: Day of surgery
Defined as the duration in hours from the first skin incision to the closure of the last incision
-
Occurrence of Intra-operative Leak Test
Time frame: During surgery
This outcome was scored as Yes or No based on whether a leak was detected during an intra-operative leak test when it was performed. Not all subjects had an intra-operative leak test performed, as it was not standard of care at all participating institutions, and so results are only presented for those subjects in whom an intra-operative test was performed.
-
Number of Subjects With 1 Chest Tube Placed
Time frame: During surgery
All subjects had either 1 or 2 chest tubes placed during surgery. Results presented are for the percentage of subjects with 1 chest tube placed.
Sponsors and collaborators
Lead sponsor
Ethicon Endo-Surgery
Industry
Registry information
Official study title
A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures
Important dates
- Study start
- 2013
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Apr 30, 2013
- Registry last updated
- Jun 18, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
NCT04563871
Bronchial Neoplasms, Carcinoma, Bronchogenic
Cheonju, South Korea
View Trial DetailsAn Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
NCT01964157
Bronchial Neoplasms, Carcinoma, Bronchogenic
Seoul, South Korea
View Trial DetailsA Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797
Bronchial Neoplasms, Carcinoma, Bronchogenic
Los Angeles, California, United States
View Trial DetailsA Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925
Bronchial Neoplasms, Carcinoma, Bronchogenic
Palo Alto, California, United States
View Trial Details